These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 31023262

  • 1. Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES).
    Kaczmarski KR, Sozio SM, Chen J, Sang Y, Shafi T.
    BMC Nephrol; 2019 Apr 25; 20(1):138. PubMed ID: 31023262
    [Abstract] [Full Text] [Related]

  • 2. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
    Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC.
    Circulation; 2011 Aug 30; 124(9):1046-58. PubMed ID: 21824920
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.
    Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA.
    Hypertension; 2013 Oct 30; 62(4):691-7. PubMed ID: 23918752
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP, Sakhuja S, Colvin CL, Clark D, Jaeger BC, Hardy ST, Howard G, Cohen LP, Irvin MR, Tanner R, Carey RM, Muntner P.
    Hypertension; 2020 Dec 30; 76(6):1953-1961. PubMed ID: 33131312
    [Abstract] [Full Text] [Related]

  • 5. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
    Bakris G, Lin PP, Xu C, Chen C, Ashton V, Singhal M.
    J Clin Hypertens (Greenwich); 2024 May 30; 26(5):500-513. PubMed ID: 38523465
    [Abstract] [Full Text] [Related]

  • 6. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA.
    J Am Soc Hypertens; 2014 Jun 30; 8(6):405-13. PubMed ID: 24952653
    [Abstract] [Full Text] [Related]

  • 7. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.
    Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER, Steigerwalt SP, Townsend RR, Weir MR, Wright JT, Rahman M, CRIC Study Investigators.
    Hypertension; 2016 Feb 30; 67(2):387-96. PubMed ID: 26711738
    [Abstract] [Full Text] [Related]

  • 8. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension.
    Gu Q, Dillon CF, Burt VL, Gillum RF.
    Am J Hypertens; 2010 Jan 30; 23(1):38-45. PubMed ID: 19851295
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of Apparent Treatment-Resistant Hypertension in the United States.
    Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P.
    Hypertension; 2019 Feb 30; 73(2):424-431. PubMed ID: 30580690
    [Abstract] [Full Text] [Related]

  • 10. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M, ALLHAT Collaborative Research Group.
    Hypertension; 2014 Nov 30; 64(5):1012-21. PubMed ID: 25259745
    [Abstract] [Full Text] [Related]

  • 11. Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data.
    Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J.
    JAMA Cardiol; 2018 Jul 01; 3(7):572-581. PubMed ID: 29800138
    [Abstract] [Full Text] [Related]

  • 12. Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease.
    Groenland EH, Bots ML, Asselbergs FW, de Borst GJ, Kappelle LJ, Visseren FLJ, Spiering W, UCC-SMART Study Group.
    Int J Cardiol; 2021 Jul 01; 334():135-141. PubMed ID: 33932429
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E, Bots ML, van Zuilen AD, Wetzels JF, Blankestijn PJ, MASTERPLAN Study Group.
    Hypertension; 2015 Nov 01; 66(5):998-1005. PubMed ID: 26351024
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Apparent Treatment Resistant Hypertension Among Stroke Survivors in Ghana.
    Sarfo FS, Ovbiagele B.
    J Stroke Cerebrovasc Dis; 2020 Dec 01; 29(12):105401. PubMed ID: 33096498
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.
    Chen J, Bundy JD, Hamm LL, Hsu CY, Lash J, Miller ER, Thomas G, Cohen DL, Weir MR, Raj DS, Chen HY, Xie D, Rao P, Wright JT, Rahman M, He J.
    Hypertension; 2019 Apr 01; 73(4):785-793. PubMed ID: 30776971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.